title: Is tissue engineering and biomaterials the future for lower urinary tract dysfunction (LUTD)/pelvic organ prolapse (POP)?
abstract: The fields of tissue engineering and regenerative medicine have seen major advances over the span of the past two decades, with biomaterials playing a central role. Although the term "regenerative medicine" has been applied to encompass most fields of medicine, in fact urology has been one of the most progressive. Many urological applications have been investigated over the past decades, with the culmination of these technologies in the introduction of the first laboratory-produced organ to be placed in a human body.1 With the quality of life issues associated with urinary incontinence, there is a strong driver to identify and introduce new technologies and the potential exists for further major advancements from regenerative medicine approaches using biomaterials, cells or a combination of both. A central question is why use biomaterials? The answer rests on the need to make up for inadequate or lack of autologous tissue, to decrease morbidity and to improve long-term efficacy. Thus, the ideal biomaterial needs to meet the following criteria: (1) Provide mechanical and structural support, (2) Maintain compliance and be biocompatible with surrounding tissues, and (3) Be "fit for purpose" by meeting specific application needs ranging from static support to bioactive cell signaling. In essence, this represents a wide range of biomaterials with a spectrum of potential applications, from use as a supportive or bulking implant alone, to implanted biomaterials that promote integration and eventual replacement by infiltrating host cells, or scaffolds pre-seeded with cells prior to implant. In this review we shall discuss the structural versus the integrative uses of biomaterials by referring to two key areas in urology of (1) pelvic organ support for prolapse and stress urinary incontinence, and (2) bladder replacement/augmentation.
authors.affiliation: Urology Department, Wake Forest University, Winston Salem, NC, USA.
authors.forename: Tamer
authors.initials: T
authors.lastname: Aboushwareb
authors.forename: Patrick
authors.initials: P
authors.lastname: McKenzie
authors.forename: Felix
authors.initials: F
authors.lastname: Wezel
authors.forename: Jennifer
authors.initials: J
authors.lastname: Southgate
authors.forename: Gopal
authors.initials: G
authors.lastname: Badlani
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D005260:Female; D006801:Humans; D008297:Male; D017773:Pelvic Floor / Q000503:physiopathology*; D056887:Pelvic Organ Prolapse / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D020127:Recovery of Function; D012038:Regeneration; D044968:Regenerative Medicine; D033581:Stem Cell Transplantation; D013526:Surgical Mesh; D023822:Tissue Engineering / Q000295:instrumentation*; D054457:Tissue Scaffolds; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000295:instrumentation*
chemical_list: D001672:Biocompatible Materials